The leaders of 18 pharmacy organizations today issued the following statement following the Food and Drug Administration’s approval of the first Emergency Use Authorization for the COVID-19 vaccine.
On Nov. 30, AMCP submitted comments on CMS draft guidance for Calendar Year (CY) 2022 Medicare Advantage capitation rate and Part C and Part D payment policies. AMCP responded to CMS’s proposed introduction of a COVID-19 measure for the 2023 Part C and Part D performance measure display page and in the Star Ratings program, pending rulemaking.
On November 20, HHS released a Final Rule that amends the discount safe harbor regulation to eliminate protections for price concessions offered by pharmaceutical manufacturers to plan sponsors and pharmacy benefit managers (PBMs) under contract with plan sponsors starting January 1, 2022.
On November 20, HHS released an Interim Final Rule with Comment Period (IFC) establishing a Most Favored Nation (MFN) Model for Medicare Part B drugs. The MFN Model will calculate the payment rate for included drugs based on a price that reflects the lowest per capita GDP-adjusted price among a group of OECD countries, with an additional flat payment based on the average payment for MFN Model drugs in 2019 adjusted quarterly for inflation.
AMCP Foundation recognizes Montrell Taylor, 2021 PharmD Candidate at Howard University College of Pharmacy, for his successful completion of the Genentech Evidence for Access Summer Internship Program.
AMCP Foundation congratulates three student pharmacists who recently completed two innovative programs on managed care pharmacy and nonprofit leadership, through the generous support of Pfizer, Inc.
AMCP Foundation proudly recognizes two student pharmacists who recently completed the Managed Care: Oncology Summer Internship program with the generous support of Pfizer, Inc.’s US Oncology Organized Customer Team.
AMCP Foundation recognizes two student pharmacists from the University of Southern California and University of Washington for the successful completion of the Specialized Summer Internship Program in Health Outcomes, sponsored by AbbVie, Inc.
Today, the Administration released a final rule, Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals, along with an interim final rule, Most Favored Nations (MFN) Model. In response, AMCP CEO Susan A. Cantrell, RPh, CAE, released the following statement.